NCT04774315

Molecular Endotypes of Chronic Idiopathic Urticaria

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.

Conditions

• Chronic Urticaria, Idiopathic

Interventions

Type	Name	Description
DRUG	Omalizumab	omalizumab 300mg SQ every 4 weeks as part of standard of care

Timeline

• Start date: 2022-01-01
• Primary completion: 2025-03-01
• Completion: 2025-03-01
• First posted: 2021-03-01
• Last updated: 2024-08-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study